NEOG
Price
$5.33
Change
+$0.10 (+1.91%)
Updated
Jul 3 closing price
Capitalization
3.42B
24 days until earnings call
PACB
Price
$1.60
Change
+$0.11 (+7.38%)
Updated
Jul 3 closing price
Capitalization
976.68M
25 days until earnings call
Interact to see
Advertisement

NEOG vs PACB

Header iconNEOG vs PACB Comparison
Open Charts NEOG vs PACBBanner chart's image
Neogen
Price$5.33
Change+$0.10 (+1.91%)
Volume$4.02M
Capitalization3.42B
Pacific Biosciences of California
Price$1.60
Change+$0.11 (+7.38%)
Volume$13.77M
Capitalization976.68M
NEOG vs PACB Comparison Chart in %
Loading...
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NEOG vs. PACB commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NEOG is a StrongBuy and PACB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (NEOG: $5.33 vs. PACB: $1.60)
Brand notoriety: NEOG and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NEOG: 65% vs. PACB: 145%
Market capitalization -- NEOG: $3.42B vs. PACB: $976.68M
NEOG [@Medical Specialties] is valued at $3.42B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NEOG’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • NEOG’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, both NEOG and PACB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NEOG’s TA Score shows that 5 TA indicator(s) are bullish while PACB’s TA Score has 6 bullish TA indicator(s).

  • NEOG’s TA Score: 5 bullish, 2 bearish.
  • PACB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NEOG is a better buy in the short-term than PACB.

Price Growth

NEOG (@Medical Specialties) experienced а +11.27% price change this week, while PACB (@Medical Specialties) price change was +24.03% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.93%. For the same industry, the average monthly price growth was +1.81%, and the average quarterly price growth was -0.17%.

Reported Earning Dates

NEOG is expected to report earnings on Sep 30, 2025.

PACB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+1.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEOG($3.42B) has a higher market cap than PACB($977M). PACB YTD gains are higher at: -12.568 vs. NEOG (-56.096). NEOG has higher annual earnings (EBITDA): 189M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. NEOG (230M). NEOG (889M) and PACB (934M) have identical debt. NEOG has higher revenues than PACB: NEOG (919M) vs PACB (201M).
NEOGPACBNEOG / PACB
Capitalization3.42B977M350%
EBITDA189M-277.28M-68%
Gain YTD-56.096-12.568446%
P/E Ratio150.80N/A-
Revenue919M201M457%
Total Cash230M631M36%
Total Debt889M934M95%
FUNDAMENTALS RATINGS
NEOG vs PACB: Fundamental Ratings
NEOG
PACB
OUTLOOK RATING
1..100
6543
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
9239
P/E GROWTH RATING
1..100
280
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEOG's Valuation (97) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that NEOG’s stock grew similarly to PACB’s over the last 12 months.

NEOG's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that NEOG’s stock grew similarly to PACB’s over the last 12 months.

NEOG's SMR Rating (93) in the Medical Specialties industry is in the same range as PACB (99) in the Biotechnology industry. This means that NEOG’s stock grew similarly to PACB’s over the last 12 months.

PACB's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for NEOG (92) in the Medical Specialties industry. This means that PACB’s stock grew somewhat faster than NEOG’s over the last 12 months.

NEOG's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for PACB (80) in the Biotechnology industry. This means that NEOG’s stock grew significantly faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NEOGPACB
RSI
ODDS (%)
Bullish Trend 3 days ago
58%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
49%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
53%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CLPFX14.270.18
+1.28%
Catalyst Nasdaq-100 Hedged Equity I
GFFDX87.640.80
+0.92%
Invesco Global Focus R5
WWLAX14.130.10
+0.71%
Westwood Quality Value Fund A
NYVRX26.880.15
+0.56%
Davis NY Venture R
DIHRX14.53-0.03
-0.21%
DFA Intl Hi Relatv Profitability Instl

NEOG and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEOG has been loosely correlated with RVTY. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NEOG jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEOG
1D Price
Change %
NEOG100%
+1.91%
RVTY - NEOG
42%
Loosely correlated
+0.41%
IQV - NEOG
40%
Loosely correlated
-0.25%
SHC - NEOG
39%
Loosely correlated
+0.90%
RDNT - NEOG
38%
Loosely correlated
N/A
QTRX - NEOG
38%
Loosely correlated
+0.87%
More